This article only represents the author's own views.

In the post-COVID era, Chinese vaccine companies are grappling with price wars and a shrinking market. Even innovative vaccines against flu, rabies or sexually transmitted viruses have fallen out of favor.Against this backdrop, vaccine developer Ab&B Bio-Tech Co. Ltd. (2627.HK) is looking to raise up to around HK$518 million ($66 million) in a Hong Kong IPO to bolster its finances for the commercial challenges ahead.

A prospectus issued on July 31 described plans to offer around 33.44 million shares at a price range of HK$12.9 to HK$15.5, with two cornerstone investors, Jiaxing Xinyang and Huatai Capital Investment, signing up for around 18% of the issuance.The offer extends until August 6, with a minimum investment of 200 shares, and trading is expected to start on August 11, according to a revised issued by the company. CITIC Securities and CMB International are acting as the joint sponsors.